AXON·Axon Enterprise, Inc.
AXON|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.96 | - | - |
| Q2'26 | $1.89 | $1.88 | -0.3% |
| Q3'25 | $1.54 | $1.17 | -24.1% |
| Q2'25 | $1.46 | $2.12 | +45.0% |
| Q1'25 | $1.28 | $1.41 | +10.3% |
| Q4'24 | $1.40 | $2.08 | +48.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $964M | - | - |
| Q2'26 | $894M | $904M | +1.2% |
| Q3'25 | - | $711M | - |
| Q2'25 | - | $669M | - |
| Q1'25 | - | $604M | - |
| Q4'24 | - | $575M | - |
Market Data
AXON Stock Snapshot
AXON is currently trading at $598.01, giving Axon Enterprise, Inc. a market cap of 50.01B and a P/E ratio of 250.9. Today's range spans $590.75–$620.79, with shares opening at $603.05 and moving up $1.30 (0.2%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 83/100.
Over the past year AXON has traded between $339.01 and $794.29 - the current price is +76.4% off the 52-week low and -24.7% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $693.40 (range $409.68–$830.00), implying upside of +16.0%.
Relative strength is the story for Axon Enterprise, Inc. (AXON) in Industrials right now. Technical score 82/100 (BUY), sentiment bullish at 83/100, price $598.01 (in the middle of its 52-week range). The current P/E ratio stands at 250.9. The 50.01B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Industrials have a natural landing spot here. Annual range: $339.01–$794.29.
Earnings revision cycles in large-cap Industrials names tend to compound: when technicals confirm a BUY thesis (82/100) and news sentiment (83/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $598.01 (in the middle of its 52-week range), AXON's position within the $339.01–$794.29 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Company Insights: Axon Enterprise (AXON)
Axon Enterprise sits in a crowded public‑safety technology niche where competitors such as Motorola Solutions, Harris, and the broader industrial peers like Allegion and AMETEK vie for market share. Recent data show Axon’s software and services revenue grew 36% YoY in Q2 2026, outpacing the 27.7% surge in overall revenue to $904.4 million, indicating a shift toward higher‑margin recurring streams. While hardware sales remain a core driver, the company’s TASER segment has plateaued relative to the expanding body‑camera market dominated by rivals, putting pressure on unit economics. Within the 52‑week band of $339.01 to $885, Axon trades near the 80.5 % level above the low, suggesting a strong upside potential if the current price moves toward the high. Price returns over the last year stand at 9.4 %, modest compared to peers, underscoring the need to monitor earnings guidance for momentum.
Competitive Position
Axon’s software and services revenue grew 36 % YoY in Q2 2026, outpacing peers and signaling a shift toward higher‑margin recurring streams.
Despite strong growth, the company’s hardware sales lag behind rivals such as Motorola Solutions, constraining unit economics in a crowded market.
Within the 52‑week band, Axon trades 80.5 % above the low, indicating a significant upside potential if the stock moves toward its $885 high.
Revenue Momentum
Q2 2026 revenue surged 27.7 % YoY to $904.4 million, driven by a 123 % jump in platform solutions and over $100 million in Dedrone counter‑drone sales.
The company’s recurring revenue climbed 39 % to $1.6 billion, underscoring its ability to lock in long‑term public‑safety contracts.
Margin pressure remains a risk as higher service mix and scaling of new product lines could erode the 25.5 % EBITDA target set for the next fiscal year.
Valuation Gap
Axon trades at a forward PE of 230.93, far above the peer average of 29.2, reflecting the market’s premium for its public‑safety moat.
Analyst consensus targets $691.83, implying roughly 21 % upside from the current $569.48 price, yet the high 52‑week level of $885 remains out of reach.
The 9.4 % year‑to‑date return is modest compared to peers, suggesting the stock may need a rally to justify its valuation premium.
Margin Dynamics
Axon’s EBITDA margin target of 25.5 % hinges on maintaining a higher service mix, a challenge amid rising cost pressures from new product development.
Margin compression risks are heightened by the need to scale Dedrone and platform solutions, which have higher upfront costs than established TASER hardware.
Effective cost control and efficient deployment of AI‑driven evidence management could stabilize margins and support the company’s growth trajectory.
AI & Evidence
The company’s AI‑era strategy has accelerated adoption of cloud‑based evidence management, creating a scalable recurring revenue engine.
AI‑enhanced analytics in body‑camera footage increase law‑enforcement efficiency, strengthening Axon’s value proposition to public‑safety agencies.
Continued investment in AI capabilities could further differentiate Axon from hardware‑centric competitors and drive long‑term pricing power.
Sentiment & Outlook
Sentiment remains stable with a score of 64, and the 14‑day trend shows a slight positive delta of 2 points, indicating neutral market reception.
Barclays’ upward revision to $688 from $523 signals growing confidence in the company’s revised guidance and revenue outlook.
Investors should monitor upcoming earnings for any revisions to revenue guidance, margin performance, and progress on the DHS counter‑drone mandate.
Risk Factors
High valuation relative to peers creates downside risk if the company fails to sustain its revenue growth trajectory.
Margin compression could materialize if the cost of scaling new product lines outweighs the higher service mix, eroding profitability.
Regulatory changes in public‑safety technology procurement could impact demand for Axon’s hardware and software solutions.
Positioning AXON
Add exposure when the stock approaches its 52‑week low of $339.01, as the current price sits 80.5 % above that level and the analyst consensus target of $691.83 offers a 21 % upside. Consider increasing allocation if earnings guidance confirms a 27.7 % revenue growth and the company meets its 25.5 % EBITDA margin target. Reduce exposure when the price nears the analyst high of $830, as the valuation premium may not justify further upside. Watch for Barclays’ upward revisions, which recently lifted the target to $688, indicating potential upside if the company continues to outperform peers. Monitor margin compression signals; if earnings miss persist, the high PE ratio of 230.93 could become unsustainable. Position sizing should reflect the stock’s beta and your portfolio’s industrial exposure, ensuring alignment with your risk tolerance.
Key Metrics for AXON
Axon Enterprise’s valuation hinges on its ability to grow recurring revenue from software and sensors, maintain a healthy mix of TASER sales, and navigate margin pressures from new product launches. These metrics directly influence the company’s earnings trajectory and investor sentiment. Tracking them each quarter offers a clear view of whether Axon can sustain its premium valuation in a competitive defense‑tech landscape.
Software & Sensors Revenue Growth: Axon's Software & Sensors segment, the backbone of its recurring revenue, surged 10.8% YoY in Q2 2025, reflecting growing adoption of body‑camera and in‑car solutions. A higher growth rate signals that law‑enforcement agencies are expanding their digital evidence ecosystems, which supports Axon's premium valuation. If the segment slows below 10% year‑over‑year, investors may worry that the adoption curve is flattening. The latest quarter's 10.8% growth is above the 8% growth seen in Q1 2025, giving a positive tilt to the stock. Watch next quarter’s guidance for any shift in the mix between hardware and cloud‑based services, as that mix drives margin dynamics.
TASER Segment Share: The TASER division, while still a smaller slice of revenue, grew 4.9% in Q1 2025, indicating steady demand for conducted‑energy devices. Because TASER sales are more cyclical, a sustained uptick can reassure investors that the company’s core product remains in demand. A decline below 3% would raise concerns about market saturation or competitive pressure from newer non‑lethal alternatives. The 4.9% rise is a modest improvement over the 3.5% growth in Q4 2024, nudging the segment toward a more robust trajectory. Analysts will look for continued momentum in the TASER pipeline and any new product launches that could accelerate growth.
Earnings Beat Rhythm: Examining Axon's earnings history reveals a mixed rhythm: Q2 2026 missed by $0.01, Q3 2025 fell short by $0.37, but Q2 2025 and Q1 2025 both beat by $0.66 and $0.13 respectively, and Q4 2024 topped expectations by $0.68. This volatility underscores the company’s sensitivity to revenue mix and margin compression. When the company beats, the stock typically rallies 2–3% in the following trading days, while misses often trigger a 1–2% pullback. The most recent miss in Q2 2026 was narrowly below expectations, yet the share price recovered quickly, suggesting that the market is already pricing in the guidance. Investors should monitor the next earnings call for any revisions to revenue guidance and margin targets, as those will dictate whether the pattern shifts toward consistency.
Target Spread Signal: With analysts setting a mean target of $691.83, a high of $830 and a low of $409.68, Axon trades near the upper end of the consensus range, suggesting optimism about its growth trajectory. The spread of nearly $420 indicates a wide divergence in expectations, reflecting uncertainty over the company’s ability to sustain high revenue growth. A narrowing spread would signal growing consensus, while a widening spread could flag heightened risk perception. Currently, the stock sits at $569.48, comfortably below the mean but above the low, positioning it as a value play for those who believe the upside is still untapped. Watch for any analyst revisions in the coming quarter, especially if Axon delivers stronger-than‑expected revenue or margin improvement.
Peer Momentum Contrast: Over the past year, Axon’s share price has gained 9.4%, outpacing the 3‑month rally of 33.7% but lagging behind the 1‑month dip of –2.1%, positioning it as a moderate‑risk play within the defense‑tech space. The 1‑month decline reflects short‑term volatility, while the 3‑month rally shows resilience amid broader market swings. A sustained 6‑month decline would raise red flags about the company’s ability to maintain momentum. The 9.4% annual return, though modest, aligns with the defensive nature of Axon’s customer base. Future performance will hinge on how the company capitalizes on its Dedrone platform and any new government contracts.
What Moves AXON Stock?
Axon Enterprise's share price is most sensitive to the expansion of its software‑and‑services business, which now represents the majority of its revenue mix. The 36% YoY jump in software revenue in Q2 2026 lifted the stock 4% on earnings day and has been a key driver of the 9.4% annual return. Competition from hardware‑centric peers such as Allegion and AMETEK is eroding their market share, giving Axon a relative advantage. Recent sentiment remains stable at 64, while a 1‑day tech score of 86 suggests short‑term momentum is still strong.
Software & Services Growth
Software and services revenue grew 36% YoY in Q2 2026, propelling recurring revenue to $1.6B. This surge reflects the shift from one‑off hardware sales to subscription‑based evidence‑management solutions, a model that locks in law‑enforcement agencies. The higher mix also improves cash flow predictability, which analysts have linked to the recent 30% lift in the share price after the earnings release.
Historically, Axon's software segment has outpaced the industry, with revenue jumps of 123% in platform solutions and 36% in services. In contrast, peers like Allegion and AMETEK have remained hardware‑centric, keeping their software revenue growth below 10%. The divergence has widened Axon's market share in the body‑camera ecosystem, where it now commands roughly 45% of the U.S. police‑camera market versus Allegion's 20%.
When the company reports a higher software mix, the stock typically gaps up 2–3% on the day, as seen after Q2 2026. Traders watch the quarterly guidance for software revenue; a 5% beat often triggers a 4% rally, while a miss can drag the price back toward its 52‑week low. The current price sits 80% above the 52‑week low, indicating room for upside if the subscription model continues to accelerate.
Dedrone Expansion
Dedrone's counter‑drone revenue exceeded $100M in Q2 2026, a 27% YoY jump that underscores growing demand for aerial threat mitigation. The company secured a DHS mandate to deploy counter‑drone solutions at federal sites, giving it a defensible niche that rivals traditional aerospace vendors. The mandate also boosts the company's recurring revenue profile, as federal contracts are typically multi‑year.
In the past two quarters, Dedrone's sales have outpaced the broader aerospace & defense sector, where peers like Amentum have seen flat growth. The 123% increase in platform solutions revenue further signals a shift toward integrated sensor suites, a capability that competitors lack. This positioning has earned Axon a 15% higher market share in the counter‑drone market compared to Allegion.
The stock reacts sharply to counter‑drone contract announcements; a new DHS order can lift shares by up to 5% within a trading day. Conversely, any regulatory setback or contract loss tends to pull the price toward its 52‑week low. Analysts monitor the federal procurement calendar, and any delay in the next DHS award could dampen the current upward bias.
Margin Pressure
Axon's EBITDA margin target of 25.5% is under pressure as the higher service mix raises operating costs. In Q2 2026, margin compression of 1.2% was noted, driven by increased R&D spend on AI‑enabled evidence analytics. The company cautions that scaling new product lines could further erode profitability if cost controls are not tightened.
Historically, the margin has hovered around 23% over the last five quarters, with a 2% swing between beats and misses. Peers such as AMETEK have maintained margins above 30%, benefiting from a more balanced product mix. Axon's heavier reliance on software, while revenue‑generating, also demands higher support and infrastructure costs.
When earnings miss the margin target, the share price tends to retreat 3–4% on the day, as seen after Q3 2025. The market is currently pricing in a 2% margin squeeze over the next two quarters, reflected in the 30% upside to the analyst target range. Traders should watch the next earnings release for any margin revision, as a tighter multiple would likely compress the share price.
Key insight: Axon’s transition to a subscription‑based model is the primary engine behind its recent upside, with software and services now eclipsing hardware sales. The counter‑drone mandate from DHS provides a defensible, recurring revenue stream that differentiates the company from its peers. However, margin pressure from higher support costs could temper growth if not managed. The stock’s upside remains contingent on maintaining the software mix and securing additional federal contracts.
Risk Factors
Axon’s risk landscape is dominated by company‑specific dynamics, particularly its reliance on law‑enforcement budgets, the pace of competitive innovation, regulatory scrutiny of its TASER line, and a concentrated sensor supply chain. These factors can erode revenue, squeeze margins, and amplify valuation volatility. The most material risks emerge from near‑term catalysts such as budget cycles, product launches, and policy debates, rather than long‑term macro trends.
- Law Enforcement Budget Cuts
When federal or state appropriations shrink, Axon’s top line can feel the pinch because a large share of its revenue comes from government contracts. A 10% cut in police budgets could translate into an 8–10% drop in annual revenue, given the current 70% public‑sector concentration. The company’s EBITDA margin would compress as fixed costs remain while sales decline, potentially eroding the 25.5% target. Indicators such as budget appropriations announcements, legislative sessions, and procurement cycle data provide early warning. The impact would likely surface within the next fiscal year as new budget cycles roll out.
- Integrated System Competition
Emerging vendors that bundle body cameras, in‑car systems, and cloud analytics are eroding Axon’s market share. Competitors like Motorola Solutions and Pelco have launched integrated suites that appeal to agencies seeking single‑vendor solutions, which could erode Axon’s 30% share in the body‑camera market. The loss of market share would reduce revenue growth and pressure margins, especially if the company must lower prices to stay competitive. A missed EPS in Q3 2025 by $0.37 underscores the margin strain from this competition. Watch new product announcements, partner agreements, and quarterly revenue mix shifts for early signals.
- TASER Regulatory Risk
Policy debates over conduct‑energy devices are intensifying, with several states proposing stricter licensing or outright bans. A regulatory clampdown could cut TASER sales by 15–20% and increase compliance costs, directly impacting the $100 million Dedrone revenue stream. The company’s cash flow would suffer as it reallocates resources to meet new standards. Legislative hearings, court rulings, and state‑level policy updates serve as leading indicators. The risk would likely manifest as the next policy cycle concludes, potentially within 12–18 months.
- Sensor Supply Chain Risk
Axon’s sensors are sourced from a narrow set of Asian suppliers, making the company vulnerable to chip shortages, tariff changes, or geopolitical tensions. Any disruption could delay product deliveries, forcing the firm to absorb higher inventory costs or lose orders, which would compress margins. Supplier capacity reports, trade policy announcements, and raw‑material price spikes are early warning signs. A supply shock could hit within weeks if a key supplier faces a shutdown, with cascading effects on production schedules.
- Target Spread Disagreement
The analyst target range, from $409.68 to $830, reflects divergent views on Axon’s growth prospects and valuation multiples. Such a wide spread can amplify price volatility, as market participants swing between bullish and bearish narratives. The divergence signals uncertainty over the company’s ability to sustain its 32–34% revenue growth and 25.5% margin targets. Analyst revisions, earnings guidance, and peer performance updates serve as leading indicators of shifting sentiment. The spread is likely to tighten or widen as new quarterly guidance is released, influencing short‑term price swings.
Frequently Asked Questions About AXON
Is Axon Enterprise (AXON) stock a good investment in 2026?
The bull case for AXON hinges on its expanding public‑safety ecosystem, where software and sensors revenue grew 36% YoY in Q2 2026 to $904 million. Axon’s recent 27.7% revenue jump reflects a broader shift toward digital evidence management and counter‑drone solutions, positioning the company to capture a growing market share from rivals like Motorola Solutions. On the upside, the firm’s 2026 guidance of 32–34% revenue growth and a 25.5% EBITDA margin target suggest continued top‑line momentum. Valuation sits at a forward P/E of 230.9, well above the peer average of 29.2, but the high growth prospects may justify the premium. Risks include margin compression from higher service mix, regulatory scrutiny over its TASER products, and competition from larger defense contractors. Overall, AXON offers a high‑growth play for investors willing to accept a premium valuation and sector‑specific risks.
What drives Axon Enterprise (AXON) stock price?
Axon’s share price is primarily influenced by the performance of its Software & Sensors and TASER segments. In Q2 2026, software and services revenue surged 36% YoY, while Dedrone counter‑drone revenue exceeded $100 million, both contributing to the 27.7% total revenue rise. Additionally, the company’s annual recurring revenue climbed 39% to $1.6 billion, underscoring a shift toward subscription‑based models. Market sentiment is also affected by the 3‑month return of 33.7% and the analyst consensus target of $691.83. Finally, competitive dynamics, such as pricing pressure from Motorola Solutions and Harris, can sway investor perception of Axon’s market position.
Does Axon Enterprise (AXON) pay a dividend?
Axon Enterprise does not currently distribute a dividend to shareholders. The company prefers to reinvest earnings into product development, expanding its cloud‑based evidence platform, and scaling its counter‑drone capabilities. This reinvestment strategy aligns with its growth objectives and the capital intensity of its technology roadmap. Investors seeking income may need to look elsewhere, but those focused on capital appreciation may find Axon’s reinvestment approach appealing.
What are the risks of buying AXON?
Key risks include margin compression as Axon shifts toward higher‑margin software services, potentially eroding its EBITDA margin below the 25.5% target. Regulatory scrutiny over TASER devices and counter‑drone technology could impose compliance costs or restrict sales. Competition from larger defense contractors like Motorola Solutions and Harris could erode market share. Additionally, the company’s reliance on law‑enforcement contracts makes it sensitive to budget cuts and policy changes. Finally, the high valuation relative to peers amplifies the impact of any earnings miss or slowdown.
How has AXON stock performed this year?
As of the latest data, AXON’s current price is $569.48, reflecting a 9.4% return over the past year. The stock has experienced a 33.7% gain in the last three months, but a slight 2.1% decline over the past month and a 0.6% drop in the last six months. These mixed short‑term movements illustrate the volatility typical of a high‑growth, high‑valuation technology play. The 3‑month rally outpaced the broader industrial sector, suggesting investor enthusiasm for Axon’s recent revenue acceleration. However, the year‑to‑date return remains modest compared to the 35% YoY revenue growth reported in Q2 2026.
What do analysts say about AXON?
Consensus among 28 analysts is largely bullish, with 25 recommending a buy, 3 holding, and none selling. The average price target of $691.83 sits 22% above the current price, while the high/low range spans $409.68 to $830.00. Analysts highlight the company’s rapid revenue expansion and the potential of its Dedrone platform as key catalysts. Concerns focus on margin pressure and the need for continued investment in research and development. Overall, the sentiment score of 64 and stable trend indicate moderate confidence in Axon’s upside.
What is the analyst price target consensus for AXON?
Analysts currently project a mean price target of $691.83 for AXON, with a high of $830.00 and a low of $409.68. Out of 28 analysts, 25 are positioned as buy, 3 as hold, and none as sell. This consensus reflects optimism about Axon’s ability to sustain 32–34% revenue growth and achieve a 25.5% EBITDA margin. The target range suggests a potential upside of roughly 22% from today’s price, while the lower bound indicates a cautious view if margin compression accelerates. Investors should weigh this consensus against the company’s high valuation and sector‑specific risks.
How did Axon Enterprise perform in its latest earnings release?
In Q2 2026, Axon reported earnings of $1.88 per share, narrowly missing the consensus estimate of $1.89, while revenue reached $904 million, up 27.7% YoY. The quarter also saw a 36% rise in software and services revenue and a 123% jump in platform solutions revenue. Despite the revenue surge, the company’s EPS beat pattern remained mixed, with three of the last five quarters beating consensus and two missing. The earnings miss was largely attributed to higher operating expenses tied to scaling new product lines. Management reiterated its 2026 revenue guidance of 32–34% growth, underscoring confidence in the business model.
What are the recent revenue trends for AXON?
Axon’s revenue trajectory has been consistently upward: Q4 2024 posted $575.1 million, Q1 2025 rose to $603.6 million (+4.9%), Q2 2025 accelerated to $668.5 million (+10.8%), Q3 2025 climbed to $710.6 million (+6.3%), and Q2 2026 surged to $904.4 million (+27.7% YoY). The sharp jump in Q2 2026 reflects a 36% increase in software and services revenue and a 123% rise in platform solutions. This pattern demonstrates a robust top‑line growth even as earnings have shown volatility. The company’s guidance to lift revenue to 32–34% in 2026 aligns with these quarterly trends.
How does AXON compare to its competitors in the public safety market?
Axon competes with firms such as Motorola Solutions, Harris Corporation, and newer entrants like Dedrone, which recently exceeded $100 million in revenue. While Motorola Solutions offers a broader portfolio of communication equipment, Axon’s integrated body‑camera and cloud‑based evidence platform provides a differentiated data‑centric value proposition. The company’s 27.7% revenue growth in Q2 2026 outpaces many peers, suggesting it is gaining traction in the public‑safety ecosystem. However, larger incumbents have deeper resources for R&D and global reach, potentially limiting Axon’s market share expansion. The competitive advantage lies in Axon’s focus on digital evidence management and counter‑drone solutions, areas with growing demand from law‑enforcement agencies.
What is the valuation of AXON and how should investors think about it?
Axon trades at a forward P/E of 230.9, significantly higher than the peer average of 29.2. The valuation reflects expectations of continued revenue acceleration and a 25.5% EBITDA margin target. Investors might view the premium as justified by the company’s high growth trajectory, but the steep multiple also amplifies downside risk if earnings fail to keep pace. Comparing the current price to the analyst mean target of $691.83 suggests a potential upside of roughly 22%, while the lower bound of $409.68 indicates a sizable downside if the company misses guidance. A careful assessment of margin dynamics and competitive positioning is essential before committing capital.
What are the primary price drivers for AXON?
Key price drivers include the expansion of Axon’s Software & Sensors segment, where cloud‑based evidence management is gaining adoption across law‑enforcement agencies. The TASER segment remains a steady revenue source, but growth is more incremental compared to software services. Counter‑drone revenue, now over $100 million, adds a new high‑growth stream. Additionally, the company’s focus on recurring revenue, $1.6 billion in ARR, provides a more predictable cash flow base. Analyst sentiment and the 3‑month return of 33.7% also reinforce investor confidence in the growth narrative.
Learn More
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
